Le Lézard
Classified in: Science and technology
Subjects: Photo/Multimedia, Merger/Acquisition

PharmAlliance Announces Acquisition of CHEORS


PharmAlliance, a diversified pharmaceutical and life sciences services platform, is pleased to announce the acquisition of Complete Health Economics Outcomes Research Solutions?CHEORS?a leading provider of health economics and outcomes research (HEOR) and market access services across the pharmaceutical, biotechnology, and medical device industries. With this addition, PharmAlliance strengthens its global reach and expands its launch and commercialization capabilities.

CHEORS marks the third strategic acquisition for PharmAlliance, a portfolio company of Waud Capital Partners. PharmAlliance acquired its first asset, BioBridges, a leading provider of clinical development services to emerging and established pharmaceutical, biotechnology, and medical device companies in August 2023. The platform then acquired Monitorforhire (MFH), now a division of BioBridges, in late 2023 to introduce a specialized service line benefitting both clients and its international network of over 4,000 clinical research professionals.

"CHEORS' excellent reputation and unique approach is an important next step in the expansion of the PharmAlliance portfolio," said Mark Bouck, Chairman & CEO of PharmAlliance and BioBridges. "Their global capabilities, client base, and exceptional HEOR/RWE services illustrate our commitment to providing our drug and device development clients with the end-to-end solutions they need."

CHEORS specializes in economic modeling, health technology assessment (HTA) submissions, evidence synthesis?including literature reviews and network meta-analyses (NMAs)?and real-world evidence (RWE) analysis. These core functions address one of the fastest-growing needs in the drug development lifecycle, supporting HEOR activities from early stages to reimbursement through lifecycle management. Renowned for exceptional customer satisfaction and technical expertise, CHEORS brings a track record of strong organic growth in the HEOR and RWE areas.

"From the outset, the synergies between CHEORS and PharmAlliance have been very attractive. Our shared values and combined expertise across the biotech and pharma sectors diversify and strengthen our service offerings and customer base, positioning us to make a significant impact," said Shalini Bagga, PhD, President of CHEORS. "Together, we offer a broader range of high-quality services, ultimately accelerating the delivery of life-changing treatments to patients."

About PharmAlliance

A pharmaceutical and life sciences services platform designed to serve a variety of discovery, development, and commercialization needs across the drug and device development lifecycle through diverse and disruptive end-to-end solutions. Since its formation, PharmAlliance has completed three strategic acquisitions consisting of BioBridges, a provider of clinical development services, Monitorforhire, a web-enabled resource management company providing access to a database of screened, qualified, and available independent clinical trial monitors, and CHEORS, a leading provider of health economics and outcomes research (HEOR) and market access services. www.pharmallianceportfolio.com

About BioBridges

BioBridges is a leading provider of drug, biologic, and device consulting services spanning development through commercialization. A trusted advisor to clients and consultants with a flexible delivery model, BioBridges provides scarce resources on a fractional basis that creates a "win-win" for both clients and consultants. www.biobridges.com

About CHEORS

Complete Health Economics Outcomes Research Solutions (CHEORS) is a leading provider of global HEOR and market access services for the pharmaceutical, biotech, and medical device industry. CHEORS provides evidence-based solutions to generate a greater understanding of the clinical and economic value of products for payers, regulators, and prescribers. www.cheors.com

About Waud Capital Partners

Based in Chicago, Waud Capital Partners ("WCP") is a growth-oriented private equity firm with over 30 years of investing experience. WCP seeks to partner with experienced management teams to build market-leading companies within two industries: healthcare and software & technology. Since its founding in 1993, WCP has successfully completed more than 460 investments, including platform companies and follow-on opportunities. www.waudcapital.com.


These press releases may also interest you

at 15:45
POET Technologies Inc. ("POET" or the "Company") , the designer and developer of the POET Optical Interposertm, Photonic Integrated Circuits (PICs) and light sources for the data center, tele-communication and AI markets, has added an additional...

at 15:36
iCivics, the nation's leading civic education nonprofit, and the White House Historical Association today launched Brief the Chief, a new digital game that teaches students how the President of...

at 15:35
On April 20, 2024, the 72 best youth free-throw makers in the nation stepped up to the line at Wintrust Arena in Chicago to take their shot at national titles in six divisions?boys and girls in each of three age-groups. While only six walked away...

at 15:34
EMERGE Commerce Ltd. ("EMERGE", or the "Company"), a premium e-commerce brand portfolio, is pleased to announce that, further to its news releases dated March 22, 2024, and April 12, 2024, 100% of the holders (the "Debentureholders") of the 10%...

at 15:33
Margex, a cryptocurrency trading platform boasting ultra-convenient and user-friendly copy trading, is excited to announce the addition of five new trading pairs to USD: Toncoin (TON/USD), Theta Network (THETA/USD), Jupiter (JUP/USD), TRON...

at 15:22
RMS Titanic, Inc., the salvor-in-possession of the RMS Titanic, today announced the dates for its 2024 Imaging and Research Expedition. The company also unveiled details about the plans for utilizing high-resolution imaging technology that will...



News published on and distributed by: